Detail akcie Akebia Therapeutics online

Business Summary: Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Akebia Therapeutics Inc revenues decreased 7% to $53.5M. Net loss totaled $9.1M vs. income of $6.1M. Revenues reflect Product revenue, net decrease of 7% to $52M. Net loss reflects Development and commercialization segment loss totaling $4.7M vs. income of $13.5M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.02595 to -$0.0339.